AC Immune SA (ACIU)
2.38
-0.03
(-1.24%)
USD |
NASDAQ |
Apr 23, 16:00
2.38
0.00 (0.00%)
After-Hours: 16:03
AC Immune Total Liabilities (Quarterly): 26.40M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 26.40M |
| September 30, 2023 | 18.93M |
| June 30, 2023 | 18.79M |
| March 31, 2023 | 17.75M |
| December 31, 2022 | 18.28M |
| September 30, 2022 | 15.90M |
| June 30, 2022 | 14.64M |
| March 31, 2022 | 23.17M |
| December 31, 2021 | 32.23M |
| September 30, 2021 | 25.87M |
| June 30, 2021 | 23.68M |
| March 31, 2021 | 21.81M |
| December 31, 2020 | 26.63M |
| September 30, 2020 | 25.41M |
| June 30, 2020 | 23.55M |
| March 31, 2020 | 23.57M |
| December 31, 2019 | 27.67M |
| Date | Value |
|---|---|
| September 30, 2019 | 23.17M |
| June 30, 2019 | 23.48M |
| March 31, 2019 | 71.34M |
| December 31, 2018 | 19.23M |
| September 30, 2018 | 17.07M |
| June 30, 2018 | 17.20M |
| March 31, 2018 | 14.88M |
| December 31, 2017 | 15.58M |
| September 30, 2017 | 13.15M |
| June 30, 2017 | 10.88M |
| March 31, 2017 | 11.54M |
| December 31, 2016 | 13.48M |
| September 30, 2016 | 14.98M |
| June 30, 2016 | 13.00M |
| March 31, 2016 | 9.187M |
| December 31, 2015 | 8.992M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
14.64M
Minimum
Jun 2022
32.23M
Maximum
Dec 2021
22.68M
Average
23.48M
Median
Jun 2019
Total Liabilities (Quarterly) Benchmarks
| Roche Holding AG | 68.11B |
| CRISPR Therapeutics AG | 346.77M |
| Addex Therapeutics Ltd | 4.163M |
| NLS Pharmaceutics Ltd | 6.557M |
| Molecular Partners AG | 26.10M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 217.65M |
| Shareholders Equity (Quarterly) | 191.25M |
| Current Ratio | 9.219 |